These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28679598)

  • 1.
    Cilia R; Laguna J; Cassani E; Cereda E; Pozzi NG; Isaias IU; Contin M; Barichella M; Pezzoli G
    Neurology; 2017 Aug; 89(5):432-438. PubMed ID: 28679598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
    Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
    Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
    Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
    J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese Mucuna pruriens (Hasshou Beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease.
    Sakata M; Miyamoto K; Koh J; Nagashima Y; Kondo T; Ito H
    Intern Med; 2024 Oct; 63(20):2773-2779. PubMed ID: 38462520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
    Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
    J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
    Lieu CA; Kunselman AR; Manyam BV; Venkiteswaran K; Subramanian T
    Parkinsonism Relat Disord; 2010 Aug; 16(7):458-65. PubMed ID: 20570206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
    Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
    J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T
    Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease.
    Lopane G; Contin M; Scaglione C; Albani F; Baruzzi A; Martinelli P
    Clin Neuropharmacol; 2010; 33(5):254-6. PubMed ID: 20852413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucuna Pruriens Combined with Carbidopa in Parkinson's Disease: A Case Report.
    Radder DLM; Tiel Groenestege AT; Boers I; Muilwijk EW; Bloem BR
    J Parkinsons Dis; 2019; 9(2):437-439. PubMed ID: 30856121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease.
    Van Blercom N; Lasa A; Verger K; Masramón X; Sastre VM; Linazasoro G
    Clin Neuropharmacol; 2004; 27(3):124-8. PubMed ID: 15190235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucuna pruriens to treat Parkinson's disease in low-income countries: Recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice.
    Caronni S; Del Sorbo F; Barichella M; Fothergill-Misbah N; Denne T; Laguna J; Urasa S; Dekker MCJ; Akpalu A; Sarfo FS; Cham M; Pezzoli G; Cilia R
    Parkinsonism Relat Disord; 2024 Jul; 124():106983. PubMed ID: 38797572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
    Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
    Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could Mucuna pruriens be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?
    Fothergill-Misbah N; Maroo H; Cham M; Pezzoli G; Walker R; Cilia R
    Parkinsonism Relat Disord; 2020 Apr; 73():3-7. PubMed ID: 32179240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
    Kasture S; Pontis S; Pinna A; Schintu N; Spina L; Longoni R; Simola N; Ballero M; Morelli M
    Neurotox Res; 2009 Feb; 15(2):111-22. PubMed ID: 19384573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.